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High levels o f cytosolic cathepsin D expression have 
been associated with poor prognosis in breast cancer 
node-negative patients. In this work, we provide 
evidence that three cell lines established from human 
metastatic melanomas-IIB-MEL-J, Im-MEL-LES, 
and Im-MEL-IAN-express high lev els of procathep-
sin D mRNA. Im-MEL-J cells secreted into the con-
ditioned media about 30% of the newly synthesized 
protein, which was active a t acidic pH. Melanoma 
tumors arising in nude mice after injection of the 
three different cell lines expressed high levels of 
procathepsin D mRNA. Moreover, 13 human met a-
static melanomas expresse d variable levels of pro-
cathepsin D mRNA. To st udy the possible association 
between cathepsin D expression and melanoma de-
he incidence of cutaneous melanoma is increasing 
rapidly throughout the world, and a sequence of 
events leading from nevocellular nevi to dysplastic 
nevi to melanoma has been proposed [1]. Human 
melanomas are characterized by their high metastatic 
capacity. Tumor invasion of the surrounding matrix is a crucial step 
in the multistage process leading to metastasis formation. Several 
types of extracellular-matrix-degrading enzymes have been impli-
cated in stroma invasion by malignant cells (see [2] and references 
therein). Some of them, like cathepsin B [3] and more recently the 
matrix metalloproteinases [4], have been associated with the inva-
sive and metastatic capacity of melanoma cells. 
A 52-kD protein secreted in excess by cultured human breast 
cancer cells has been found to be similar to the aspartyl protease, 
cathepsin D [5,6]. This lysosomal endopeptidase is produced under 
normal conditions as a 52-kD inactive proenzyme, and is processed 
intracellularly into an intermediate 48-kD form and a 34-kD 
mature form [5]. Consistent with normal processing, normal mam-
mary cells secrete in vitro less than 5% of the newly synthesized 
procathepsin D. In contrast, breast cancer cell lines may secrete up 
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velopment, samples corresponding to 10 primary tu-
mors, 11 metastatic melanomas, 10 dysplastic nevi, 27 
nevocellular nevi, and normal melanocytes were 
studied by immunohistochemistry for cathepsin 
D-specific staining. We found that cathepsin D was 
expressed in all of the dysplastic nevi and primary 
and metastatic melanomas tested but in only 18% of 
nevocellular nevi (five of 27), whereas normal mela-
nocytes showed no cathepsin D expression. The over-
all data indicate that cathepsin D is expressed at a 
high level by melanoma cells, and because of its 
expression in preneoplastic lesions, it may be associ-
ated with melanoma development. J Invest Dermatol 
104:340-344, 1995 
to 60% of the inactive proenzyme as a result of altered processing 
of the 52-kD precursor at the level of its interaction with man-
nose-6 P-receptors [7]. 
Secreted procathepsin D, activated under mild acidic conditions, 
is capable of digesting the extracellular matrix of endo thelial bovine 
corneal cells, suggesting its potential role in tumor invasion [8]. 
Indeed, increased cathepsin D expression in human breast cancer 
has been associated with a worse prognosis [9] . 
A previous report showed cathepsin D expression in some human 
melanomas [10]. In the present study, we confirm and extend th ose 
results by showing that the great majority of primary and metastatic 
melanomas and dysplastic nevi express high levels of cathepsin D, 
whereas only five of27 common acquired nevocellular nevi express 
cathepsin D and normal melanocytes express none. The present 
data suggest that the expression of this aspartyl protease might be 
associated with melanoma development. 
MATERIALS AND METHODS 
Cell Lines and Proteinase Assay The IIB-MEL-J cell line was derived 
from a metastatic human melanoma [11]. The IIB-MEL-LES and IIB-MEL-
IAN human melanoma cell lines, also derived from metastatic melanomas, 
were established in our laboratory and will be described elsewhere. The 
estrogen-receptor (ER)-positive breast cancer cell line MCF-7 and the 
ER-negative breast cancer cell lines MDA-MB-231 and IIB-BR-G have 
been described [12-14]. To assay the proteinase activity in conditioned 
media, IIB-MEL-J cells were cultured in the absence of fetal bovine serum 
for 18 h , after which the medium was recovered. The proteinase activity 
was measured using hemoglobin [15] or (methyl-14C)methemoglobin [5] as 
substrate. In experiments involving proteinase inhibitors, pepstatin A and 
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leupeptin at the concentrations mentioned ill the Results were added 
immediately before the assay. 
Immunoprecipitation Assay Exponentially growing Illi-MEL-J cells 
were plated, 105 each, into 35-mm Petri dishes and labeled with [35S]me_ 
thionine. The medium and the cells were collected separately to perform an 
immunoprecipitation assay with the monoclonal antibody DSF5, which 
recognizes the 52-kD procathepsin D and the intermediate and mature 
forms of the enzyme [16]. The labeling and processing of the cells have been 
described previously [5]. 
Tumor Cell Dissociation, RNA Extraction, and Northern Analysis 
Total RNA was obtained either from exponentially growing cultures of 
melanoma cell lines or from metastatic tumors. Briefly, recently excised 
metastatic tumors were trimmed rapidly of fat and necrotic tissue and 
conserved in liquid nitrogen until use. Alternatively, metastatic tumors were 
cut in small fragments and dissociated mechanically by pressing through a 
nylon mesh until a cell suspension was obtained. Isolated cells were 
cryopreserved until use [14]. Cell viability was estimated with the trypan 
blue dye exclusion test. For RNA preparation, tumor fragments or cells 
were thawed, washed twice with phosphate-buffered saline, and resus-
pended in buffer containing sodium isothiocyanate. If necessary, cells were 
disrupted with a Polytron homogenizer. Total RNA was obtained as 
described [17], electrophoresed in 1% agarose gels in the presence of 
formaldehyde, transferred to nylon membranes (Hybond N, Amersham), 
and hybridized with random-primed cDNA probes (106 cpm/ml). RNA 
integrity and loaded amount were checked with methylene blue. Mter 6-S 
h of pre-hybridization, the membranes were hybridized overnight at 42°C 
with 50% formamide. Membranes were washed under high stringency 
conditions, twice with 2 X sodium citrate/sodium chloride buffer, 0.1 % 
sodium dodecylsulfate at room temperature, and four times with 0.1 X 
sodium citrate/sodium chloride buffer, 0.1 % sodium dodecylsulfate at 55°C 
[lS]. The human procathepsin D cDNA probe is a 2.0 -kilobase-pair EeoR! 
insert [5]. 
Human melanomas were induced in mice using exponentially growing 
melanoma cells, which were harvested by trypsinization, washed with 
culture medium without serum, and resuspended in phosphate-buffered 
saline. Five million cells in a volume of 0.1 ml were injected subcutaneously 
into the flanks of6-S-week-old male nude mice (BALB/c-nu/nu). Tumors 
1 cm in diameter were used for RNA extraction, as described above. 
ImmunochemicaI Determinations Paraffin-embedded tissue blocks 
were used to detect cathepsin D by immunohistochemistry. Slices 5 JLm 
thick were mounted on gelatin-coated slides by standard procedures. 
Melanin pigments were eliminated from hydrated sections as described [19]. 
Melanin removal was checked routinely by use of a control with phosphate-
buffered saline instead of the first antibody. Cathepsin D was detected 
immunohistochemically with a commercial monoclonal antibody (Triton 
Diagnostics, Alameda) . An avidin-biotin bridge was used following the 
manufacturer's instructions (Vectastain, Vector Laboratories). The reaction 
was developed with 0.02% diaminobenzidine and hydrogen peroxide. 
Staining intensity was scored as follows: 1 + = low intensity; 2+ = 
moderate intensity; 3 + = strong intensity. Cathepsin D expression in 
normal melanocytes corresponds to that in normal areas adjacent to benign 
pathologies and in well-preserved autopsies. 
An ER-immunocytochemical assay monoclonal antibody (Abbott Labo-
ratories, North Chicago, IL) was used for ER determination on melanoma 
cells. 
RESULTS 
Human Melanoma-Cell-Conditioned Medium Contains Pro-
teases Active at Acidic pH Initial experiments using hemoglo-
bin as substrate indicated that conditioned medium obtained from 
human melanoma IIB-MEL-J cells contained proteinase activity 
with an optimum acidic pH. By using [methyl-14C] methemoglo-
bin, we found that IIB-MEL-J-conditioned medium solubilized 8% 
± 4% of total trichloroacetic-acid-precipitable radioactivity after 60 
min incubation and 15% ± 3% after 120 min incubation (mean ± 
SD of three different experiments) at pH 4.0 [5]. Twenty-six 
percent of this activity was inhibited upon the addition of the 
aspartyl protease inhibitor pepstatin A at 10- 6 M. That pepstatin A 
did not completely prevent the protease activity of IIB-MEL-J cells 
at acidic pH suggested the presence of additional proteases. Indeed, 
32% inhibition was observed in the presence of the cysteine 
protease inhibitor leupeptin at 10- 6 M, indicating the presence of 
active serine and/or cysteine proteases. 
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Cathepsin D is Secreted by Human Melanoma Cells The 
pepstatin inhibition of proteinase activity at acidic pH prompted us 
to investigate whether an activated human melanoma cathepsin D 
could be responsible for this activity. For this purpose, we used a 
monoclonal antibody raised against the human breast cancer pro-
cathepsin D that recognizes both the inactive precursor and the 
mature forms [16]. An immunoprecipitable 52-kD band corre-
sponding to the secreted procathepsin D was found in the Iffi-
MEL-J-conditioned medium. Moreover, the 34-kD mature form 
of cathepsin D was immunoprecipitated from cell homogenates 
(Fig 1). 
Quantitative analysis also demonstrated that approximately 30% 
of the newly synthesized procathepsin D was secreted into the 
medium after a 16-h labeling period (data not shown). This 
secretion is not under estradiol regulation in the IIB-MEL-J cell 
line, as the addition of 10- 9 M estradiol in the absence of phenol 
red for 48 h to Iffi-MEL-J cells deprived of estradiol for 5 d did not 
affect the secretion of procathepsin D. In addition, Iffi-MEL-J cells 
were found to express no ER by immunocytochemical analysis 
(data not shown). 
Cathepsin D mRNA is Expressed by Established Human 
Melanoma Cell Lines The high levels of procathepsin D ob-
served in the Iffi-MEL-J-conditioned medium correlated with high 
levels of mRNA expression. Northern blot analysis has shown that 
IIB-MEL-J cells as well as Iffi-MEL-LES and Iffi-MEL-IAN cells 
expressed high levels of a 2.2-kilobase-pair band corresponding to 
the expected size of procathepsin D mRNA. This expression was 
comparable to the levels observed with different ER-positive and 
ER-negative human breast cancer cell lines (Fig 2). 
To evaluate whether the expression of procathepsin D in human 
melanoma cells is the result of cell adaptation to growth in vitro, we 
also determined procathepsin D mRNA levels in melanomas 
induced in nude mice by injection of the three different cell lines. 
Figure 2 shows high levels of pro cathepsin D mRNA expression in 
all the tumors tested, suggesting that the constitutive expression of 





Figure 1. Immunoprecipitation of the 52-kD procathepsin D and 
the 34-kD mature enzyme from the cellular extract and condi-
tioned medium ofIIB-MEL-J cells. Mter labeling of cells with e5S]me-
thionine, the conditioned medium (A,B) and cellular extract (C,D) were 
obtained from Illi-MEL-J cells and were immunoprecipitated as described 
in Materials and Methods with the DSF5 monoclonal antibody (B,D) or with 
normal mouse immunoglobulins (A,C). 
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Figure 2. Human melanoma cell lines and melanoma tumors 
induced in nude mice express cathepsin D mRNA levels compara-
ble to those expressed by human breast cancer cell lines. Twelve 
micrograms of total RNA was loaded in each lane, electrophoresed, 
transferred to nylon membranes, and hybridized with a human cathepsin D 
probe. Cell lines used were two ER-negative (MDA-MB-231 and lill-
BR-G) and one ER-positive (MCF-7) breast cancer cell lines and three 
human melanoma cell lines (IIB-MEL-LES, lill-MEL-J , and lill-MEL-
IAN). Nude mice tumors were human melanoma tumors obtained in nude 
mice as described in Materials and Methods. The positions of the 28 S and the 
18 S ribosomal RNAs are indicated. M ethylene blue staining of nylon 
membranes shows RNA integrity and comparable loading. 
this aspartyl protease in human melanomas is not a result of growth 
in culture. 
Cathepsin D mRNA is Expressed by Human Metastatic 
Melanomas Because cultured cells are not necessarily represen-
tative of malignant cells in the intact tissues from which they were 
derived, we studied the expression of cathepsin D in human 
metastatic melanoma samples by Northern and immunohistochem-
ical analyses. Tissue fragments or isolated cells corresponding to 24 
cryopreserved human metastatic melanomas were used for total 
RNA extraction. Mter checking RNA integrity by methylene blue 
staining (Fig 3), we selected 13 samples for Northern blot analysis. 
As with the established melanoma cell lines, only a 2.2-kilobase-
pair procathepsin D mRNA band was detected in all the tumor 
samples examined. High procathepsin D mRNA levels were ob-
served in four samples, moderate levels in six, and low levels in 
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Figure 3. Human metastatic melanomas express cathepsin D 
mRNA. Eight micrograms of total RNA was loaded in each lane (for 
further details see Fig 2 and Materials and Methods). The sources of RNA 
were as follows: isolated cells, samples 1-4 and sample 6; tumor fragments, 
sample 5 and samples 7-13. The sites of origin of the metastases were as 
follows: lung l sample 1; lymph nodes, samples 2,3,5, 7, 9, 10, and 12; derma, 
samples 4, 6, and 11; brain, sample 8; viscera, sample 13. Sex of the patients 
was female, in samples 4, 7, and 11. The positions of the 28 S and 18 S 
ribosomal RNAs are indicated. Methylene blue staining of nylon mem-
branes shows RNA integrity and comparable loading. 
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three (Fig 3). We found no correlation between mRNA proca-
thepsin D expression and the origin of the metastasis or of the 
samples (from tumor fragments or isolated cells). 
Immunohistochemical Detection of Cathepsin D in Pri-
mary and Metastatic Melanoma and Dysplastic Nevi Be-
cause previous reports have shown that cathepsin D can be 
expressed by both malignant and nonmalignant host-infiltrating 
cells [20], we performed an immunohistochemical analysis to 
evaluate cathepsin D distribution in melanomas. All of the 10 
metastatic melanomas tested expressed intracytoplasmic cathepsin 
D (Table I, Fig 4a,b), although wide variability was observed in 
the staining intensity and in the percentage of cells expressing 
cathepsin D (Table I). In those samples studied by both Northern 
and immunohistochemical analyses, we found that low expression 
of mRNA correlated with low to moderate staining intensity and 
with less than 40% positive cells. 
By immunohistochemical analysis, cathepsin D was found to be 
expressed preferentially by the malignant cells, although infiltrating 
macrophages also expressed it (Fig 4c,d). In six of 10 metastatic 
melanoma samples, as well as in all the primary melanomas tested 
(see below), cathepsin D expression was fourid to be associated 
with fine granules distributed throughout the cytoplasm (Fig 4a). 
However, in four metastatic melanomas, cathepsin D expression 
was associated with clusters of perinuclear granules with net 
borders (Fig 4b). No evidence of stromal reactivity or of staining of 
lymphocytes or muscle cells was observed. However, macro-
phages, sebaceous glands, sweat glands, and some epidermal kera-
tinocytes showed staining (Fig 4c,d). To determine the significance 
of cathepsin D expression in melanomas, we performed further 
studies in primary melanomas, benign nevocellular nevi, dysplastic 
nevi, and normal melanocytes (see below). In these cases, cathepsin 
D expressIon was studied only by immunohistochemistry because 
of the small amount of material available. Intracytoplasmic staining 
was observed in all of the 11 primary melanomas tested and in 
approximately 90% of cells (Table I, Fig 4c) . Nine primary 
melanomas showed intense intracytoplasmic staining, and the re-
maining two samples expressed cathepsin D with moderate inten-
sity (Table I). 
All of the 10 dysplastic nevi analyzed by immunohistochemistry 
expressed cathepsin D with moderate (two of 10) to strong (eight 
of 10) intensity and with an overall mean cell positivity of 82% 
(range 55%-95% of malignant cells; see Table I and Fig 4eJ). 
Similarly, all three Spitz nevi analyzed showed strong intensity of 
cathepsin D expression (data not shown). However, only five of27 
nevocellular nevi showed low (two of five) to moderate (three of 
five) intracytoplasmic expression of cathepsin D (Table I). Only 
Table I. Immunohistochemical Detection of Cathepsin 
D 
Number of Type of 
Lesion Cases 0 
Primary tumors 11 
Metastases 10 
Dysplastic nevi 10 
Nevocellular nevi 27 22 
Staining IntensityQ 
1+ 2+ 3+ 
2 9 
(65, 70) [80-100] 
94.4 :::'::: 8.3 
1 1 8 
(15) (60) [35-100] 
63.7 :::'::: 29.4 
2 8 
(55, 50) . [76-95] 
88.3 :::'::: 6.8 
2 3 
(7, 5) [10-60] 
28.3 :::'::: 22.5 
a Staining intensity was sco;ed as described in Materials and Methods. Data are 
presented as the number of positive cases, percentage of positive cells in each case (in 
parentheses), range of positive cells in percentage (in brackets), and mean :±:: SD 
percentage of positive cells. 
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Figure 4. Immunohistochemical detection of cathepsin D in mel-
anoma and dysplastic nevi. Sections obtained from paraffin-embedded 
tissues were stained by the immunoperoxidase method as described in 
Materials and Methods. a,b) Metastatic melanomas; c) primary melanoma; d) 
compound nevocellular nevus; e,j) nevi with a dysplastic component. a) 
Peritoneal metastasis; intense staining is observed in the cytoplasm of 
malignant cells (arowheads). b) Perinuclear cathepsin D is observed (arrow-
head). c) nodular fusocellular primary melanoma. Intense staining is ob-
served in neoplastic melanocytes (Mel) and macrophages (A). Lymphocytes 
(Ly) do not stain. d) Moderate staining is observed in intraepidermal nests of 
type A nevus cells disposed along the dermoepidermal junction (A) and in 
type B nevus cells (B). e) Dysplastic and dermal nevus. Intense staining is 
observed in the atypical melanocytic hyperplasia at the dermoepidermal 
junction (arrowhead). See also the negative dermal nevus (DN) . j) Dysplastic 
nevus showing the granular intracytoplasmic staining in cells of the 
junctional nests (arrowhead). Bars: a,b, 2.3 JLm; c, 4 JLm; d, 23 JLm; e, 15 JLm; 
J, 3.1 JLm. 
two of the 27 samples were compound nevi, and in both cases the 
junctional component consisting of type A nevus cells and intra-
dermal type B nevus cells expressed cathepsin D (Fig 4d). The 
remaining 25 cases corresponded to dermal-nevus-containing type 
B cells. On the other hand, normal intraepidermal and follicular 
melanocytes showed no expression of cathepsin D (not shown). 
DISCUSSION 
This study confirms and extends a previous work [10] by showing 
that all the primary and metastatic human melanomas and dysplastic 
nevi tested expressed, in most cases strongly, the aspartyl protease 
cathepsin D, suggesting a role for this protease in the development 
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of melanoma. High levels of cytosolic cathepsin D protein have 
been suggested as a marker of poor prognosis in primary breast 
cancer [9,21,22]. High levels of this protein also were associated 
with shorter recurrence-free survival and overall survival in breast 
cancer patients, leading to the suggestion that cathepsin D expres-
sion by malignant cells may be associated with the capacity of tumor 
cells to invade [9]. It has also been shown that cathepsin D levels 
correlate with an increased risk for developing breast cancer in 
highly proliferative benign mastopathies [10]. 
More extensive studies with clinical follow-up are warranted to 
confirm that cathepsin D expression can be useful as a predictive 
marker in melanoma development. The expression of cathepsin D 
by all of the melanoma samples and proliferating precursor lesions, 
but only in part of the nevocellular nevi analyzed and not at all in 
normal melanocytes, argues in favor of this possibility. Our results 
show that 100% of the dysplastic nevi samples studied express high 
levels of cathepsin D. Although some controversy persists concern-
ing the diagnosis of dysplastic nevi, this lesion is widely considered 
a precursor of melanoma, especially for individuals in melanoma-
prone families, as well as a marker of high risk for melanoma. 
Indeed, 17% to 30% of sporadic melanomas have been associated 
with dysplastic nevi [23]. 
The strong staining we observed in the three Spitz nevi studied 
and the expression of cathepsin D in part of the acquired nevi 
should be investigated further. Spitz nevi are the result of spindle 
cell proliferation downward from the dermoepidermal junction. 
Histologically, cell nuclei appear normal, but as in dysplastic nevi, 
atypical mitotic figures usually are found. Occasional documenta-
tion has suggested that this lesion may metastasize [1]. On the other 
hand, in a recent histologic review, it was found that 15.4% of 
melanomas were associated with contiguous benign nevi, usually 
arising from the intraepidermal or junctional component [1]. 
One of the most controversial aspects concerning this aspartyl 
protease is the possible involvement of the tumor-cell- derived 
cathepsin D in cancer invasion. The studies linking high levels of 
cathepsin D expression to a worse prognosis in breast cancer were 
based on the immunologic detection of cathepsin D and did not 
differentiate between the precursors and active forms or between 
the origin of the enzyme from tumor or host-infiltrating cells 
[9,21]. In conflict with these findings, a recent immunohistochem-
ical study reported that a high level of intracytoplasmic cathepsin D 
expressed by the malignant cells, rather than the cathepsin D level 
in tissue homogenates, is a marker of better prognosis [23]. This is 
in agreement with what one would expect for a gene initially 
described in breast cancer to be under estrogen regulation [24], 
although recent data have shown, in agreement with our results, 
that ER-negative breast cancer cell lines constitutively express 
cathepsin D [8]. This conflicting evidence concerning the predic-
tive value of cathepsin D expression in human breast cancer, and a 
more recent article showing that secreted cathepsin D does not 
contribute to the in vitro invasive capacity of MCF-7 cells [25], 
raised the possibility that macrophage-derived cathepsin D also 
might be involved in breast cancer invasion. The data presented 
here demonstrate that cathepsin D is expressed constitutively by 
malignant melanoma cells. The Iffi-MEL-J cell line does not 
contain ER; nor was an ER-independent pathway of cathepsin D 
regulation observed upon estrogen addition in the absence of 
phenol red. Immunohistologic studies of primary and metastatic 
melanomas identified a comparatively low level of host-infiltrating 
cells expressing cathepsin D, which suggests that cathepsin D is 
contributed mostly by tumor cells. 
Whatever role cathepsin D could have as a prognostic marker, it 
is still difficult to understand its function as an extracellular protease 
when it is virtually inactive at pH 7.0. Some clues concerning the 
mechanism by which it might participate directly in matrix degra-
dation have emerged recently. In vitro studies have demonstrated 
that procathepsin D secreted by breast cancer cells and autoacti-
vated at acidic pH may degrade the extracellular matrix of endo-
thelial bovine corneal cells [8]. More recently, it was shown that 
cathepsin D localized in intracytoplasmic acidic vesicles may par-
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nClpate in cancer invasion either at the intracellular level, by 
degrading endocytosed extracellular matrix, or at the extracellular 
level, by releasing the vesicles' content, transiently creating an 
extracellular acidic environment [26], as has been reported during 
bone resorption [27]. By histologic analysis, we have found that in 
all primary melanomas and some metastases, cathepsin D is associ-
ated with fine granules, most probably corresponding to lysosomal 
or endosomal vesicles distributed throughout the cytoplasm. How-
ever, in some metastatic tumors (but not in primary tumors), 
cathepsin D staining was found to be associated with perinuclear 
large vesicles several micrometers in size, resembling the large 
acidic vesicles found previously in human breast cancer samples 
[26]. It remains to be established whether these differences in the 
structure and localization of cathepsin D-containing vesicles cor-
respond to differences in lysosomal enzyme targets. 
An indirect role for cathepsin D in extracellular matrix degrada-
tion arose from recent data linking cathepsin D with the cysteine 
protease cathepsin B, a lysosomal protease that has been associated 
with the metastatic capacity of B 16 mouse melanom~ cells [3,28]. 
The inhibitiQn of procathepsin B maturation is eliminated by the 
aspartyl protease inhibitor pepstatin A, which strongly suggests a 
role for cathepsin D in this process [29]. Evidence was presented 
that only cathepsin D can inactivate the specific cysteine protease 
inhibitor cystatin, leading to increased activity of cysteine proteases 
like cathepsin B [30]. The activation of cathepsin B in turn may 
result in the transformation of procollagenase [31] and pro-uroki-
nase plasminogen activator [32] to their active forms, initiating the 
process of extracellular matrix degradation [4]. 
It is interesting that only part of the proteinase activity released 
by melanoma cells into conditioned media appears to be aspartic 
proteases, as the activity is not inhibited completely in the presence 
of pepstatin A, a strong inhibitor of aspartyl protease activity at 
acidic pH. This is strikingly different from what was reported 
previously for MCF-7 breast cancer cells, i.e., that pepstatin A 
completely inhibited the protease activity of M CF-7 - conditioned 
medium at acidic pH [8]. Moreover, the serine and cysteine 
protease inhibitor leupeptin, which was almost inactive on MCF-
7-conditioned medium [8], partially inhibited the protease activity 
of IIB-MEL-Jcells at acidic pH, suggesting that melanoma cells 
secrete into the extracellular media cysteine proteases like cathepsin 
B, which may interact with cathepsin D for their mutual processing 
and activation. Recent data showing that B 16 mouse melanoma 
cells express cathepsins D and B mRNAs, among other cathepsin 
rnRNAs [28], support this hypothesis. 
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